LITMUS Imaging Study

NCT05479721 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2025-04-16

No results posted yet for this study

Summary

The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.

Conditions

  • NAFLD
  • NASH
  • NASH - Nonalcoholic Steatohepatitis
  • Fibrosis, Liver
  • Steatosis of Liver

Sponsors & Collaborators

  • Newcastle University

    collaborator OTHER
  • University of Nottingham

    collaborator OTHER
  • University of Cambridge

    collaborator OTHER
  • University of Seville

    collaborator OTHER
  • Pinnacle Clinical Research, PLLC

    collaborator OTHER
  • ICAN Nutrition Education and Research

    collaborator INDUSTRY
  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER
  • University of Angers

    collaborator UNKNOWN
  • University of Palermo

    collaborator OTHER
  • University of Turin, Italy

    collaborator OTHER
  • University Medical Center Mainz

    collaborator OTHER
  • University of Helsinki

    collaborator OTHER
  • University of Bern

    collaborator OTHER
  • Linkoeping University

    collaborator OTHER_GOV
  • Perspectum

    collaborator INDUSTRY
  • Antaros Medical

    collaborator INDUSTRY
  • Resoundant Inc

    collaborator UNKNOWN
  • Pfizer

    collaborator INDUSTRY
  • Novartis

    collaborator INDUSTRY
  • Takeda

    collaborator INDUSTRY
  • Intercept Pharmaceuticals

    collaborator INDUSTRY
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER
  • Boehringer Ingelheim

    collaborator INDUSTRY
  • University of Oxford

    lead OTHER

Principal Investigators

  • Michael Pavlides, MBBS, DPhil · University of Oxford

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-04
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • United States
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05479721 on ClinicalTrials.gov